Surveillance des réponses immunitaires au vaccin contre la COVID-19 chez les personnes vivant avec le VIH-1

People who are immunosuppressed or suffering from chronic inflammatory diseases have an increased risk of complications linked to SARS-CoV-2 infection, in addition to often having a diminished vaccine response. People living with HIV (PLHIV) also have chronic inflammation, which makes them more susceptible to complications. We will analyze the immune response of a cohort of 100 PLHIV vaccinated against COVID-19 and followed every six months at the UHRESS of the University Hospital of Quebec. Information on COVID-19 vaccination and risk factors leading to severe COVID will be collected. Serological and cellular immunity analyzes (innate and acquired) will be carried out at entry and at 6 months. A cohort of 200 vaccinated people working in retail (PTCD) and for whom we already have data will be used as a comparative group. We propose to complete this transdisciplinary analysis with the study of the innate immune response in PLHIV by analyzing neutrophil responses. Indeed, the human neutrophil being the most abundant leukocyte in the blood circulation and an important player in the development of the innate and inflammatory immune response, we hypothesize that measuring the intensity of the functional responses of the neutrophil could predict good vaccination protection, while being different between the cohorts of PLHIV and PTCD. This study will make it possible to characterize the elements of the innate immune response of PLHIV to the COVID-19 vaccine, in addition to establishing correlations between the cellular response and different serological markers, with the aim of suggesting or not a third dose of vaccine. or the addition of anti-inflammatory treatment. This project will be carried out by a multidisciplinary team covering clinical and fundamental aspects of virology, as well as functional immune responses including the neutrophil.